DOCSLIB.ORG

Practical Comparison of LC-MS/MS-Based Workflows For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Practical Comparison of LC-MS/MS-Based Workflows For Practical comparison of LC-MS/MS-based workflows for quantitation of desmosine and isodesmosine in urine – potential lung damage biomarkers in premature infants Karolina M. Krasinskaa, Carlos Millab, Stephen R. Lynchc , Allis S. Chiena aVincent Coates Foundation Mass Spectrometry Laboratory; bDepartment of Pediatrics; cNMR Facility; Stanford University, Stanford, CA Overview LC-MS/MS platforms Results TABLE 1. Comparison of technical features. Analysis of DES and IDES in straight urine is only possible with methods A and C. This work compares the feasibility of three LC-MS/MS- Instrumentation FIGURE 2. Comparison of LC conditions. Three mobile phase Strong matrix effect and poor sensitivity has been observed when modifiers were evaluated for DES/IDES separation in matrix free using method B. Of all three, method A utilizes the most mass based workflows for the quantitation of desmosine (DES) LC system: Agilent HP 1100 samples: 0.1% formic acid (A), 5 mM HFBA/5 mM AA (B) and spectrometry compatible LC mobile phases but does not allow and isodesmosine (IDES) in urine samples MS detection: Waters Quattro Premier triple quadrupole MS 0.5% TFA (C). With each eluent system, several gradient, baseline resolution of DES and IDES. Ionization mode: positive ESI Each of the tested methods, with its advantages and temperature and flow rate settings were tested. The best results Scanning mode: Selected Reaction Monitoring (SRM) disadvantages, proves to be suitable for quantitative for each modifier and its respective column are presented below. Comparison criterion ABC analysis *) LC conditions 1uM DES/IDES, 0.1uM PYR IS new Hypercarb, 100x2.1mm, 3um, A: 0.1% FA in water, B: 0.1% FA in MeOH LLOQ in solvent / urine 5 / 10 fmol 5-10 / 200 fmol 50 / 5 fmol MillaC_130118_40328_15 Sm (Mn, 1x1) MRM of 6 Channels ES+ 4.60 526.3 > 83.6 (DES/IDES) 5.42e5 Time – Sample analysis 10 min 10 min 10 min Time IDES AB C %B 4.71 [min] DES Chromatographic resolution Not sufficient for Introduction baseline baseline 02 Hypercarb Atlantis T3 Hypercarb (DES/IDES separation quantitation 0.3 2 Column (Thermo Fisher Scientific) (Waters) (Thermo Fisher Scientific) Hypercarb Matrix interference **) % Minor Significant Not observed Desmosine (DES) and isodesmosine (IDES) are lysine- 100 mm x 2.1 mm, 3 µm 2.1 mm x 100 mm, 3 µm 100 mm x 2.1 mm, 3 µm A 640 (urine – no sample prep) 740 0.1% FA derived pyridinium amino acids, byproducts of the Column Hypercarb Atlantis T3 Hypercarb Mobile Phase A 0.1% FA 5 mM HFBA/ 5 mM AA 0.5% TFA 7.5 2 destruction of elastin. Release of these two compounds to 10 2 Mobile phase modifier 0.1% FA 5 mM HFBA/5 mM AA 0.5% TFA 5 mM HFBA/ 5mm AA in 0 Time Mobile Phase B 0.1% FA in acetonitrile 0.5% TFA 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 body fluids serves as an indicator of elastin degradation 80% acetonitrile Flow rate [µl/min] 250 250 300 100nM DES/IDES, Atlantis T3, 100x2.1mm, 3um, A: 5mM HFBA/5mM AA, B: 5mM HFBA/5mM AA/80% Acetonitrile associated with lung damage in bronchopulmonary MillaC_130116_40328_77 Sm (Mn, 3x2) MRM of 6 Channels ES+ *) matrix interferences made sensitivity assessment inaccurate and irreproducible Flow rate 250 µL/min 250 µL/min 300 µL/min 5.52 526.3 > 83.6 (DES/IDES) 6.32e4 **) method B is not feasible for analysis of straight urine. In order to achieve good sensitivity and reproducibility dysplasia (BPD), a significant cause for morbidity and Time IDES 1 %B biological sample need extensive sample preparation (solid phase extraction) as described by Ma et al. mortality among infants born prematurely. This study FA: formic acid; HFBA: heptafluorobutyric acid; AA: ammonium acetate; TFA: trifluoroacetic acid [min] 01 DES 5.96 evaluates three LC-MS/MS based workflows – differing FIGURE 1. Analytes. Desmosine (DES) and Isodesmosine 0.3 1 Atlantis T3 mainly in chromatography – for quantitation of DES and (IDES) are positional isomers which generate nearly identical CID B % 620 Conclusions 7.5 20 5 mM HFBA/AA IDES. Comparison criteria include sensitivity, fragmentation patterns. Due to this similarity, MS analysis is not 81 Each of the tested methods can be applied to the quantitative chromatographic resolution, matrix interference, sufficient to distinguish between these two isomers. The H-NMR 10 1 analysis of DES and IDES in urine samples – however, each has 0 Time robustness, and total speed of analysis. Key goals were spectra of DES and IDES reveal significant differences for the 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 advantages and disadvantages which must be considered in pyridine ring protons at high field [ppm]. 500nM DES/IDES, 500nM PYR IS, 0.1%FA context of project requirements: reduction of sample preparation time and use of volatile LC MillaC_130521_42199_36 Sm (Mn, 3x2) MRM of 6 Channels ES+ 7.62 526.3 > 83.6 (DES/IDES) 2.83e4 Methods B and C achieve baseline resolution of two isomeric Time IDES eluents. This study illustrates practical choices which must %B [min] DES analytes. However, current clinical data do not support the be made in developing and selecting a fit-for-purpose 7.97 DES IDES 010 necessity of quantifying DES and IDES individually – so analytical method. 0.3 10 Hypercarb C % 630 chromatographic separation, while satisfying analytically, may 4 730 0.5% TFA be extraneous. 7.5 10 8.18 Method A is the most MS compatible and would be best suited 10 10 Sample preparation 6 2 6 1 Time for large scale measurement of combined DES and IDES, as its 3.00 4.00 5.00 6.00 7.00 8.00 9.00 run time can be significantly shortened to provide high- Standards: throughput analysis. Powdered desmosine (DES) and FIGURE 3. Analysis of human urine samples. Urine samples Both methods B and C utilize ion paring agents; of the two, TFA isodesmosine (IDES) were purchased from 33 infants were analyzed using method A. The cohort is more MS friendly than HFBA, in that it is more volatile, easier from Elastin Product Company. includes 18 premature and 15 full term newborns. Of the to wash out, and causes less ionization suppression. IDES_NEW_MSMS_02 19 (0.452) Cm (2:20) Daughters of 526ES+ DES_SIGMA_MSMS_02A 12 (0.322) Sm (Mn, 2x1.00); Cm (3:29) Daughters of 526ES+ 397.2 2.63e7 481.3 1.61e6 Successful application of Method B requires extensive, time Acetylated pyridinoline was obtained from 100 526.4 100 83.7 premature babies, 7 developed bronchopulmonary dysplasia Quidel as a 3.8 µM solution (in 90% (BPD) and 11 did not. No obvious correlation among disease consuming sample preparation, while methods A and C work 526.3 397.2 state, age and prematurity was observed in this set of samples. well with straight urine. % % 352.2 acetic acid) and used as an Internal 352.1 527.3 83.6 436.3 PYR IS 481.1 129.8 Due to its sensitivity, chromatographic resolution and lack of 129.9 Standard (PYR IS). 85.7 392.0 291.0 308.2 191.9 247.1 307.4 matrix interferences, Method C is our choice for this ongoing 0 m/z 0 m/z Stock solution: 1 mM in 50% acetonitrile/0.1% formic acid 50 100 150 200 250 300 350 400 450 500 550 600 100 150 200 250 300 350 400 450 500 550 600 project. Working solutions: 50 µM; prepared by dilution of stock Analyte Abbreviation MW SRM LC-MS/MS solution with water Calibration curve: 0.1 nM – 5000 nM prepared by serial Desmosine DES 525.3 526.3 > 83.6, 397.1, 481.3 Future work dilutions in matrix-free solvent or urine Isodesmosine IDES 525.3 526.3 > 83.6, 397.1, 481.3 The measured levels of DES/IDES in infant urine did not Biological samples: Urine samples were collected from Acetylated pyridinoline PYR IS 470.1 471.1 > 81.8, 128.0, 267.2 support the use of DES/IDES as biomarkers for BPD. Future 33 human infants: 15 normal controls and 18 premature work will concentrate on the analysis of plasma and airway fluid H-C6 samples using the established LC-MS/MS workflow. babies. Of the premature babies, 7 developed lung disease H-C2 and 11 did not. Creatinine levels were used for H-C6 References H-C4 normalization purposes. 1) Ma,S.; Turino,G.; Lin,Y.Y. J.Chrom.B 2011, 879: 1893-1898 Acknowledgements Thanks to the Vincent and Stella Coates Foundation and NIH Grant Award Number 1P01HL108797. All biological samples were injected as-is, without any Thanks to Anne Coates, MD and Julie Kim, MD for sample procurement. sample cleanup or dilution. This poster may be downloaded from the Stanford University Mass Spectrometry website at http://mass-spec.stanford.edu/Publications.html 61st ASMS Conference, June 9-13, 2013, Minneapolis, MN.
Load more

Recommended publications
  • Collagen and Elastin Fibres
    J Clin Pathol: first published as 10.1136/jcp.s3-12.1.49 on 1 January 1978. Downloaded from J. clin. Path., 31, Suppl. (Roy. Coll. Path.), 12, 49-58 Collagen and elastin fibres A. J. BAILEY From the Agricultural Research Council, Meat Research Institute, Langford, Bristol Although an understanding of the intracellular native collagen was generated from type I pro- biosynthesis of both collagen and elastin is of collagen. Whether this means that the two pro- considerable importance it is the subsequent extra- collagens are converted by different enzyme systems cellular changes involving fibrogenesis and cross- and the type III enzyme was deficient in these linking that ensure that these proteins ultimately fibroblast cultures, or that the processing of pro become the major supporting tissues of the body. type III is extremely slow, is not known. The latter This paper summarises the formation and stability proposal is consistent with the higher proportion of collagen and elastin fibres. of soluble pro type III extractable from tissue (Lenaers and Lapiere, 1975; Timpl et al., 1975). Collagen Basement membrane collagens, on the other hand, do not form fibres and this property may be The non-helical regions at the ends of the triple due to the retention of the non-helical extension helix of procollagen probably provide a number of peptides (Kefalides, 1973). In-vivo biosynthetic different intracellular functions-that is, initiating studies showing the absence of any extension peptide rapid formation of the triple helix; inhibiting intra- removal support this (Minor et al., 1976), but other cellular fibrillogenesis; and facilitating transmem- workers have reported that there is some cleavage brane movement.
    [Show full text]
  • Synthetic Polynucleotides Synthetische Polynukleotide Polynucleotides Synthetiques
    Europäisches Patentamt *EP000960192B1* (19) European Patent Office Office européen des brevets (11) EP 0 960 192 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C12N 9/02, C12N 15/53, of the grant of the patent: A61K 38/43, C12N 9/06 09.11.2005 Bulletin 2005/45 (86) International application number: (21) Application number: 97933592.4 PCT/AU1997/000505 (22) Date of filing: 11.08.1997 (87) International publication number: WO 1998/006830 (19.02.1998 Gazette 1998/07) (54) SYNTHETIC POLYNUCLEOTIDES SYNTHETISCHE POLYNUKLEOTIDE POLYNUCLEOTIDES SYNTHETIQUES (84) Designated Contracting States: • SHARP P M ET AL: "The codon Adaptation AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC Index--a measure of directional synonymous NL PT SE codon usage bias, and its potential applications." NUCLEIC ACIDS RESEARCH. (30) Priority: 09.08.1996 AU PO156596 ENGLAND 11 FEB 1987, vol. 15, no. 3, 11 February 1987 (1987-02-11), pages 1281-1295, (43) Date of publication of application: XP001122356 ISSN: 0305-1048 01.12.1999 Bulletin 1999/48 • DATABASE SWISSPROT [Online] 1 December 1992 (1992-12-01) MARIANI T.J. ET AL.: (60) Divisional application: "Protein-lysine 6-oxidase precursor (EC 05000327.6 1.4.3.13) (Lysyl oxidase)." Database accession no. P28300 XP002229125 (73) Proprietor: THE UNIVERSITY OF SYDNEY • DATABASE EMBL [Online] EBI; 16 May 1992 Sydney, New South Wales 2006 (AU) (1992-05-16) MARIANI T.J. ET AL.: "Human lysyl oxidase (LOX) mRNA, complete cds." Database (72) Inventor: WEISS, Anthony, Steven accession no. M94054 XP002229126 Randwick, NSW 2031 (AU) • DATABASE EMBL [Online] EBI; 26 November 1993 (1993-11-26) HAMALAINEN E.R.
    [Show full text]
  • Methods, Compounds, Compositions and Vehicles for Delivering 3-Amino-1-Propanesulfonic Acid
    (19) TZZ _ T (11) EP 2 862 581 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 22.04.2015 Bulletin 2015/17 A61K 47/48 (2006.01) C07K 5/06 (2006.01) C07K 5/08 (2006.01) C07C 309/15 (2006.01) (2006.01) (2006.01) (21) Application number: 14200552.9 C07D 207/16 C07D 209/20 C07D 217/24 (2006.01) C07D 233/64 (2006.01) (2006.01) (2006.01) (22) Date of filing: 12.10.2007 C07D 291/02 C07D 333/24 C12P 11/00 (2006.01) A61K 38/07 (2006.01) A61K 38/08 (2006.01) A61P 25/28 (2006.01) (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AT BE BG CH CY CZ DE DK EE ES FI FR GB GR yet been filed HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: Hoffmann Eitle Patent- und Rechtsanwälte PartmbB (30) Priority: 12.10.2006 US 851039 P Arabellastraße 30 12.04.2007 US 911459 P 81925 München (DE) (62) Document number(s) of the earlier application(s) in Remarks: accordance with Art. 76 EPC: This application was filed on 30-12-2014 as a 07875176.5 / 2 089 417 divisional application to the application mentioned under INID code 62. (71) Applicant: BHI Limited Partnership Laval, QC H7V 4A7 (CA) (54) Methods, compounds, compositions and vehicles for delivering 3- amino-1-propanesulfonic acid (57) The invention relates to methods, compounds, that will yield or generate 3APS, either in vitro or in vivo.
    [Show full text]
  • Revised ST.26 – 26/Oct/2016 ANNEX I
    Revised ST.26 – 26/Oct/2016 ANNEX I ST.26 - ANNEX I CONTROLLED VOCABULARY Final Draft TABLE OF CONTENTS SECTION 1: LIST OF NUCLEOTIDES ................................................................................................................................. 2 SECTION 2: LIST OF MODIFIED NUCLEOTIDES .............................................................................................................. 2 SECTION 3: LIST OF AMINO ACIDS ................................................................................................................................... 4 SECTION 4: LIST OF MODIFIED AND UNUSUAL AMINO ACIDS ..................................................................................... 5 SECTION 5: FEATURE KEYS FOR NUCLEIC SEQUENCES ............................................................................................ 6 SECTION 6: QUALIFIERS FOR NUCLEIC SEQUENCES ................................................................................................ 21 SECTION 7: FEATURE KEYS FOR AMINO ACID SEQUENCES ..................................................................................... 40 SECTION 8: QUALIFIERS FOR AMINO ACID SEQUENCES ........................................................................................... 47 SECTION 9: GENETIC CODE TABLES ............................................................................................................................. 48 Revised ST.26 – 26/Oct/2016 ANNEX I SECTION 1: LIST OF NUCLEOTIDES The nucleotide base codes to be used in sequence
    [Show full text]
  • Program 1..154
    The 97th Annual Meeting of CSJ Program Chair: INOUE, Haruo（15：30～15：55） Room S1 1S1- 15 Medium and Long-Term Program Lecture Artificial Photosynthesis of Ammonia（RIES, Hokkaido Univ.）○MISAWA, Hiroaki （15:30～15:55） Fourth Building, Section B J11 Chair: INOUE, Haruo（15：55～16：20） 1S1- 16 Medium and Long-Term Program Lecture Mechanism of water-splitting by photosystem II using the energy of visible light（Grad. Sustainable and Functional Redox Chemistry Sch. Nat. Sci. Technol., Okayama Univ.）○SHEN, Jian-ren（15:55～ ） Thursday, March 16, AM 16:20 （9：30 ～9：35 ） Chair: TAMIAKI, Hitoshi（16：20～16：45） 1S1- 01 Special Program Lecture Opening Remarks（Sch. Mater. & 1S1- 17 Medium and Long-Term Program Lecture Excited State Chem. Tech., Tokyo Tech.）○INAGI, Shinsuke（09:30～09:35） Molecular Dynamics of Natural and Artificial Photosynthesis（Sch. Sci. Tech., Kwansei Gakuin Univ.）○HASHIMOTO, Hideki（16:20～16:45） Chair: ATOBE, Mahito（9：35 ～10：50） 1S1- 02 Special Program Lecture Polymer Redox Chemistry toward Chair: ISHITANI, Osamu（16：45～17：10） Functional Materials（Sch. Mater. & Chem. Tech., Tokyo Tech.）○INAGI, 1S1- 18 Medium and Long-Term Program Lecture Recent pro- Shinsuke（09:35～09:50） gress on artificial photosynthesis system based on semiconductor photocata- 1S1- 03 Special Program Lecture Organic Redox Chemistry Enables lysts（Grad. Sch. Eng., Kyoto Univ.）○ABE, Ryu（16:45～17:10） Automated Solution-Phase Synthesis of Oligosaccharides（Grad. Sch. Eng., Tottori Univ.）○NOKAMI, Toshiki（09:50～10:10） （17：10～17：20） 1S1- 04 Special Program Lecture Redox Regulation of Functional 1S1- 19 Medium and Long-Term Program Lecture Closing re- Dyes and Their Applications to Optoelectronic Devices（Fac.
    [Show full text]
  • Growth, Elastin Concentration, and Collagen Concentration of Perinatal Rat Lung: Effects of Dexamethasone
    003 1-3998/87/2 106-0603$02.00/0 PEDIATRIC RESEARCH Vol. 21, No. 6, 1987 Copyright O 1987 International Pediatric Research Foundation, Inc Printed in U.S. A. Growth, Elastin Concentration, and Collagen Concentration of Perinatal Rat Lung: Effects of Dexamethasone JEAN-CLAUDE SCHELLENBERG, GRAHAM C. LIGGINS, AND ALISTAIR W. STEWART Postgraduate School of Obstetrics and Gynaecology [J-C.S., G.C.L.] and Department of Community Health [A. W.S.], The University of Auckland, Auckland, New Zealand ABSTRACT. The ontogenesis of elastin and collagen ac- phological (8) or biochemical structural analysis is required. cumulation and growth of the lung were studied in Wistar Although elastin and collagen have been used as markers of rats from day 18 of gestation until day 30 postnatally. connective tissue structure of the lung in newborn and adolescent Dexamethasone phosphate 0.1 mg or normal saline solu- rats (9-12), no data are available on the fetal rat lung. The tion every 8 h for three doses was injected into pregnant present study reports the ontogenesis of collagen and elastin rats on day 17. The effects of treatment, age, and sex on accumulation in rat lung between day 18 of gestation and day lung wet weight, lung dry weight, body weight, DNA, 30 postpartum and investigates the effects of prenatal glucocor- protein and desmosine (estimated by radioimmunoassay), ticoid administration on growth and structural development of and hydroxyproline were determined in the offspring. Dex- the rat lung. A radioimmunoassay for the determination of amethasone inhibited lung growth and, to a lesser extent, desmosine, a specific cross-link amino acid of elastin (13) is body weight gain.
    [Show full text]
  • WO 2010/037397 Al
    (12) INTERNATIONALAPPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 8 April 2010 (08.04.2010) WO 2010/037397 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 38/17 (2006.01) C07K 14/705 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/48 (2006.01) GOlN 33/50 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/DK2009/050257 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 1 October 2009 (01 .10.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every PA 2008 0 1381 1 October 2008 (01 .10.2008) DK kind of regional protection available): ARIPO (BW, GH, 61/101,898 1 October 2008 (01 .10.2008) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): DAKO TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, DENMARK A/S [DK/DK]; Produktionsvej 42, DK-2600 ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Glostrup (DK).
    [Show full text]
  • Liberation of Desmosine and Isodesmosine As Amino Acids from Insoluble Elastin by Elastolytic Proteases
    Liberation of desmosine and isodesmosine as amino acids from insoluble elastin by elastolytic proteases The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Umeda, Hideyuki, Masanori Aikawa, and Peter Libby. 2011. “Liberation of Desmosine and Isodesmosine as Amino Acids from Insoluble Elastin by Elastolytic Proteases.” Biochemical and Biophysical Research Communications 411, no. 2: 281–286. Published Version doi:10.1016/j.bbrc.2011.06.124 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32605695 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA NIH Public Access Author Manuscript Biochem Biophys Res Commun. Author manuscript; available in PMC 2012 July 29. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Biochem Biophys Res Commun. 2011 July 29; 411(2): 281±286. doi:10.1016/j.bbrc.2011.06.124. Liberation of Desmosine and Isodesmosine as Amino Acids from Insoluble Elastin by Elastolytic Proteases Hideyuki Umeda, Ph.D., Masanori Aikawa, M.D., Ph.D., and Peter Libby, M.D. Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, USA Abstract The development of atherosclerotic lesions and abdominal aortic aneurysms involves degradation and loss of extracellular matrix components, such as collagen and elastin. Releases of the elastin cross-links desmosine (DES) and isodesmosine (IDE) may reflect elastin degradation in cardiovascular diseases.
    [Show full text]
  • Proteins: Form, Function, and Pathology Adrian Poniatowski Studyaid Biochemistry Seminar March 2, 2019 Biochemical Origami the Structure of Proteins
    Proteins: Form, Function, and Pathology Adrian Poniatowski StudyAid Biochemistry Seminar March 2, 2019 Biochemical Origami The Structure of Proteins • From primary to quaternary structure • Pathologies are caused by misfolded proteins which are destabilized by seemingly minor amino acid changes • Form strictly defines function in the protein world • Tertiary structure will often be most clinically significant Primary Structure • Sequence of AA in protein • Creates robust bond resistant to • Read from N- (amino) to C- enviro chgs & flexible for folding (carboxyl) terminal • Dehydration synthesis • Peptide bond: covalent bond • Determines all higher structures between -NH3 (amino) and – COOH (carboxyl) groups α Helix (1 PP chain) Secondary Structure β Sheet (2+ PP chains) • α helix most common (3.6 AA/turn) • Stabilized by H-bonds b/w carbonyl O’s and amide N’s • β sheets can be parallel or antiparallel to each other • β sheets always have R-hand twist & form core of globular proteins Tertiary Structure • Hydrophobic side chains in interior, hydrophilic outside • Disulfide bridges between sulfide cont side chains provide covalent bond that provide max stability • H-bonds, ionic bonds, hydrophobic interactions contribute to architecture • Domains = fxnal 3D protein units • Denaturation affects 3-ary & 2-ary structures Protein Modification Folding & Denaturation • Chaperone proteins (HSP’s) sometimes coordinate the folding process • Denaturation is irreversible in proteins folded by HSP’s Ubiquitination • Regulates intracellular degradation of protein • Addition of one or more ubiquitin molecules to protein localizes it to proteasome for digestion Review Question Damaged cytosolic proteins are labeled with (1) and then are degraded by a protein complex called (2): A. (1) ubiquitin (2) translocon B.
    [Show full text]
  • ST.25 Page: 3.25.1
    HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION Ref.: Standards – ST.25 page: 3.25.1 STANDARD ST.25 STANDARD FOR THE PRESENTATION OF NUCLEOTIDE AND AMINO ACID SEQUENCE LISTINGS IN PATENT APPLICATIONS Revision adopted by the SCIT Standards and Documentation Working Group at its eleventh session on October 30, 2009 It is recommended that Offices apply the provisions of the “Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in International Patent Applications Under the Patent Cooperation Treaty (PCT)” as set out in Annex C to the Administrative Instructions under the PCT, mutatis mutandis, to all patent applications other than the PCT international applications, noting that certain provisions specific to PCT procedures and requirements may not be applicable to patent applications other than PCT international applications(*). The text of that PCT Standard is reproduced on the following pages. (*) If, on July 1, 2009, the national law and practice applicable by an Office is not compatible with the provisions of paragraph 3(i) of the “Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in International Patent Applications Under the Patent Cooperation Treaty (PCT)” requiring that a sequence listing which is contained in the international application as filed “shall be presented as a separate part of the description, be placed at the end of the application, preferably be entitled ‘Sequence Listing’, begin on a new page and have independent page numbering”, that Office may choose not to follow those provisions for as long as that incompatibility continues. en / 03-25-01 Date: December 2009 HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION Ref.: Standards – ST.25 page: 3.25.2 ANNEX C STANDARD FOR THE PRESENTATION OF NUCLEOTIDE AND AMINO ACID SEQUENCE LISTINGS IN INTERNATIONAL PATENT APPLICATIONS UNDER THE PCT INTRODUCTION 1.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,999,716 B2 Gundlach Et Al
    US0089997 16B2 (12) United States Patent (10) Patent No.: US 8,999,716 B2 Gundlach et al. (45) Date of Patent: Apr. 7, 2015 (54) ARTIFICIAL MYCOLIC ACID MEMBRANES USPC ..................................... 977/712 714; 436/71 See application file for complete search history. (75) Inventors: Jens Gundlach, Seattle, WA (US); Ian M. Derrington, Seattle, WA (US); Kyle W. Langford, University Place, WA (56) References Cited (US) U.S. PATENT DOCUMENTS (73) Assignee: University of Washington, Seattle, WA 6,171,830 B1* 1/2001 Verschoor ..................... 435.134 (US) 6,406,880 B1 6/2002 Thornton 2002/0052412 A1* 5/2002 Verschoor et al. ............ 514/557 - r 2004, OO63200 A1 4/2004 Chaikof (*) Notice: sity is titly 2006/0008519 A1 1/2006 Davidsen et al. ............. 424/450 U.S.C. 154(b) by 0 days. (Continued) (21) Appl. No.: 13/592,030 FOREIGN PATENT DOCUMENTS JP O7-248329 A 9, 1995 (22) Filed: Aug. 22, 2012 WO 2007041621 A2 4, 2007 (65) Prior Publication Data OTHER PUBLICATIONS US 2013/0146456A1 Jun. 13, 2013 Butler, T. Z. et al. “Single-molecule DNA detection with an engi Related U.S. Application Data neered MspA protein nanopore'. Proceedings of the National Acad .S. App emy of Science USA, vol. 105, No. 52, Dec. 30, 2008, p. 20647 (63) Continuation of application No. 2O652* PCT/US2011/025960, filed on Feb. 23, 2011. (Continued) (60) Provisional application No. 61/307,441, filed on Feb. fEEE application No. 61/375,707, Primary Examiner — J. Christopher Ball • 1- ws (74) Attorney, Agent, or Firm — Christensen O'Connor (51) Int. Cl.
    [Show full text]
  • Altered Glycosylation in Pancreatic Cancer: Development of New Tumor Markers and Therapeutic Strategies
    ALTERED GLYCOSYLATION IN PANCREATIC CANCER: DEVELOPMENT OF NEW TUMOR MARKERS AND THERAPEUTIC STRATEGIES Pedro Enrique Guerrero Barrado Per citar o enllaçar aquest document: Para citar o enlazar este documento: Use this url to cite or link to this publication: http://hdl.handle.net/10803/671007 ADVERTIMENT. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs. ADVERTENCIA. El acceso a los contenidos de esta tesis doctoral y su utilización debe respetar los derechos de la persona autora. Puede ser utilizada para consulta o estudio personal, así como en actividades o materiales de investigación y docencia en los términos establecidos en el art. 32 del Texto Refundido de la Ley de Propiedad Intelectual (RDL 1/1996).
    [Show full text]